retatrutide phase 2 trial type 2 diabetes weight loss New GLP-3 drug significantly slashes both and blood sugar levels in III 🤔Adults with type 2 diabetes

Sustainable fat loss is a metabolic problem, not a medication problem

Extended heat exposure or temperatures above 30 degrees may reduce potency measurably

The higher concentration means smaller injection volumes, which some researchers prefer

But CagriSema's 6-12 month head start, proven semaglutide component, and strong diabetes data position it well for first-mover advantage

What actually happens when you take GLP-1 a day early Understanding the theory is useful

A key finding: at 24 weeks, participants had not yet reached a plateau, suggesting the weight loss curve with retatrutide may continue longer than with tirzepatide